Uppsala, Sweden – 20 September 2017
Beactica AB, the Swedish drug discovery company, today announced that its LSD1 programme has been selected for both an oral and a poster presentation at the 15th Annual Discovery on Target Conference (www.discoveryontarget.com). The conference will take place on September 25–29, 2017 at The Westin Copley Place in Boston, MA.
Dr Ulf Bremberg, Chief Scientific Officer, to speak on Tuesday 26th September 2017 at 2:55 pm EST on "LSD1 Modulation by Allosteric Ligands”.
Organised by Cambridge Healthtech Insitute, the conference is “The Industry’s Preeminent Event on Novel Drug Targets” that this year gathers over 1,200 drug discovery professionals in Boston, MA. The event brings forth current and emerging “hot” targets, technologies and validation strategies for the development of novel small molecules and biologics.
Beactica AB is a specialist drug discovery company, utilising its proprietary methodologies to evaluate the interactions of molecules in order to generate novel therapeutics. As well as progressing its own drug discovery programmes in areas of unmet medical need, Beactica offers partnerships for fragment-based lead generation using its proprietary discovery platform. Founded in 2006 based on research carried out at Uppsala University, Beactica has established a reputation as a world-leader in fragment-based drug discovery using SPR biosensor technology. For more information on Beactica, please visit www.beactica.com.
Per Källblad M.Sc. Ph.D.
Tel: +46 18 56 08 80
Sign up for the Beactica newsletter to receive our latest news and updates